Diligence memo · auto-generated · as of July 2, 2026

Arch Biopartners Inc.

Arch Biopartners Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Arch Biopartners Inc. operates in Biotechnology, based in TORONTO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Arch Biopartners Inc. has raised $561K in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $265K on 2015-01-12.

Most recent recorded round closed around 2015-01-12.

Valuation (modeled)modeled

Provath models Arch Biopartners Inc. at approximately $15M (range $141K–$166M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.92× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era. Within the normal band (92% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 5 months.

Last raise 11.5 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.7× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 12% of Biotechnology peers (4293 compared).

Modeled value ranks above 24% of those peers.

Closest niche peers: Imanis Life Sciences, LLC, Truminim, LLC, Direct Spinal Therapeutics, Inc., Universal Biosensors Inc, One World Lab, Inc..

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.